文献速递前列腺癌

前列腺癌检测所需MRI-超声融合靶向活检针数:根治性前列腺切除术后多变量病变分析

Minimum Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective, Lesion Based Analyses of Patients Treated with Radical Prostatectomy.
PubMed 文献 · J Urol · 2019-09-04

本研究基于771例根治性前列腺切除术病例,分析每处PI-RADS≥3病变所需靶向活检针数以检测前列腺癌。结果显示79%癌症经首针检出,92%经第二针,98%经第三针,100%经第四针或以上;PI-RADS 3、4、5首针检出率分别为67%、79%、87%。多变量分析中既往阴性系统穿刺次数和病理分期为独立预测因素,提示检测临床显著前列腺癌需≥2针靶向活检。

要点

  • 多数前列腺癌可经2针靶向活检检出,少数需3针或以上
  • 首针检出率随PI-RADS评分升高而增加(3分67%,4分79%,5分87%)
  • 既往阴性系统穿刺次数和病理分期提示需≥2针靶向活检

核心结论

  • 基于根治性前列腺切除术的分析表明,大多数癌症仅需2针靶向活检即可检出,少数病例需3针或以上。

研究设计与样本

  • 回顾性多变量病变水平分析,纳入771例连续接受根治性前列腺切除术的病例,共分析1459处PI-RADS≥3的可疑前列腺癌MRI病变。

主要发现

  • 前列腺癌经初始、第二、第三、第四或以上靶向活检的检出率分别为79%、92%、98%和100%。
  • PI-RADS 3、4、5病变的首针靶向活检检出率分别为67%、79%和87%。
  • 多变量分析显示,既往阴性系统经直肠超声引导穿刺次数和病理肿瘤分期是需≥2针靶向活检以检测临床显著前列腺癌的独立预测因素。

关键数值与推荐

  • 总队列771例中,437例(57%)为系统穿刺初治,334例(43%)有1次或以上既往阴性系统穿刺。
  • 最大PI-RADS评分为3、4、5的患者分别为67例(8.7%)、567例(74%)和137例(18%)。

临床怎么用

  • 对于PI-RADS≥3的前列腺癌可疑病变,靶向活检可考虑至少2针以平衡检出率与操作负担。
  • 既往多次阴性系统穿刺或病理分期较高的患者,可能需要增加靶向活检针数以确保检出临床显著前列腺癌。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We analyzed the number of multiparametric magnetic resonance imaging targeted biopsy cores per lesion needed to detect prostate cancer in patients treated with radical prostatectomy. MATERIALS AND METHODS: Analyses focused on targeted biopsy of magnetic resonance imaging lesions suspicious for prostate cancer with a PI-RADS® (Prostate Imaging Reporting and Data System) score of 3 or greater and consecutive radical prostatectomy. Descriptive statistics included the frequency/proportion and IQR. Multivariable logistic regression analyses on the per lesion level were used to predict the number of targeted biopsies with prostate cancer. RESULTS: In the total cohort of 771 radical prostatectomy cases 437 (57%) and 334 (43%) were systematic transrectal ultrasound guided biopsy naïve or had 1 or more prior negative systematic transrectal ultrasound guided biopsies, respectively. A maximum PI-RADS score of 3, 4 and 5 was present in 67 (8.7%), 567 (74%) and 137 patients (18%), respectively. A total of 1,459 multiparametric magnetic resonance imaging lesions suspicious for prostate cancer were identified for analysis. Prostate cancer was detected based on an initial, second, third, or fourth or greater targeted biopsy in 79%, 92%, 98% and 100% of cases, respectively. The rate of prostate cancer detection on the first targeted biopsy core increased with higher PI-RADS scores of 3, 4 and 5 (67%, 79% and 87%, respectively). The number of prior negative systematic transrectal ultrasound guided biopsies and pathological tumor stage emerged as independent predictors on multivariate analysis, addressing the need for 2 or more targeted biopsy cores to detect clinically significant prostate cancer. CONCLUSIONS: Radical prostatectomy based analyses demonstrated that most cancers could be detected by 2 targeted biopsies only while in a minority of cases 3 or more targeted biopsies were necessary. Such findings might indicate that the targeted biopsy procedure and the related technology have improved, especially in patients with intermediate/high risk prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Leyh-Bannurah SR, Kachanov M, Beyersdorff D, et al. Minimum Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective, Lesion Based Analyses of Patients Treated with Radical Prostatectomy. J Urol. 2019. PMID: 31483694. doi:10.1097/JU.0000000000000527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。